

# CITATION REPORT

List of articles citing

**Tadalafil population pharmacokinetics in patients with erectile dysfunction**

**DOI: 10.1007/s00228-007-0297-1**

**European Journal of Clinical Pharmacology, 2007, 63, 583-90.**

**Source:** <https://exaly.com/paper-pdf/43064165/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
14	The use of phosphodiesterase 5 inhibitors with concomitant medications. <i>Journal of Endocrinological Investigation</i> , <b>2008</b> , 31, 799-808	5.2	49
13	Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives. <i>Patient Preference and Adherence</i> , <b>2009</b> , 3, 105-11	2.4	9
12	Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. <i>American Journal of Lifestyle Medicine</i> , <b>2009</b> , 3, 201-211	1.9	1
11	Tadalafil. <i>Profiles of Drug Substances, Excipients and Related Methodology</i> , <b>2011</b> , 36, 287-329	3	13
10	The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. <i>Pharmacogenetics and Genomics</i> , <b>2011</b> , 21, 820-8	1.9	12
9	Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 3418-32	1.1	71
8	Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction. <i>Drugs and Aging</i> , <b>2012</b> , 29, 771-81	4.7	8
7	Plasma concentrations of tadalafil in children with pulmonary arterial hypertension. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 576-83	3.2	14
6	Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies. <i>European Urology</i> , <b>2014</b> , 65, 455-64	10.2	29
5	Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors. <i>Drugs and Aging</i> , <b>2014</b> , 31, 425-39	4.7	10
4	Comparison of tadalafil pharmacokinetics after administration of a new orodispersible film versus a film-coated tablet. <i>Drug Design, Development and Therapy</i> , <b>2018</b> , 12, 935-942	4.4	5
3	Effect of supersaturation on absorption of indomethacin and tadalafil in a single pass intestinal perfusion rat model, in the absence and presence of a precipitation inhibitor. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2020</b> , 151, 108-115	5.7	8
2	Pharmacokinetic and Bioequivalence Evaluation of 2 Tadalafil Tablets in Healthy Male Chinese Subjects Under Fasting and Fed Conditions. <i>Clinical Pharmacology in Drug Development</i> , <b>2021</b> ,	2.3	1
1	Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2021</b> ,	4.5	1